A tumor-targeted trimeric 4-1BB-agonistic antibody induces potent anti-tumor immunity without systemic toxicity

Marta Compte(Recombinant Antibody Technology (United Kingdom)), Luis Álvarez‐Vallina(Spanish National Cancer Research Centre)

Nature Communications

November 9, 2018

10.1038/s41467-018-07195-w

Cited by 143

Related Papers

ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy

|OncoImmunology|2017|81